Cereno Scientific (NASDAQ First North: CRNO B) has announced initial learnings from its 12-month expanded access program with lead candidate, oral, once-daily CS1, in pulmonary arterial hypertension (PAH), confirming favorable safety and tolerability over long-term treatment.
According to Cereno, the data is consistent with previous Phase 2a results.
In a statement, Rahul Agrawal, CMO and head of R&D at Cereno, commented, “These results provide important confirmation that the favorable safety and tolerability profile observed in the Phase 2a trial is maintained over longer-term use. In PAH, where existing therapies can be associated with safety and tolerability challenges, there remains a significant unmet need for safer, well-tolerated treatment options. These findings support the continued development of CS1 as a potential disease-modifying therapy.”
Sten R. Sörensen, CEO of Cereno, added, “The accumulated clinical Phase 2 data representing up to 15 months of treatment with CS1 in patients with PAH provides us with further confidence in our goal to develop and deliver CS1 as a new treatment for patients with PAH. The results from the EAP study support the value proposition of CS1 as an oral, once-daily PAH therapy with a favorable safety and tolerability profile and potential disease-modifying effects.”
